Bisphosphonate‐related osteonecrosis of the jaw: data from the French national pharmacovigilance database |
| |
| Authors: | Paul de Boissieu Louise Gaboriau Aurore Morel Thierry Trenque |
| |
| Affiliation: | 1. Department for Pharmacovigilance and Pharmacoepidemiology, Reims University Hospital, Reims, France;2. Faculty of Medecine, University of Reims Champagne‐Ardenne, Reims, France;3. Pharmacovigilance regional Centre, Medical Pharmacology, Lille, France |
| |
| Abstract: | The aim of this study was to describe bisphosphonate‐related osteonecrosis of the jaw (BRONJ) in the French national pharmacovigilance database. BRONJ was identified with the standardized MedDRA query (SMQ) ‘osteonecrosis’ among all data from 1985 to 31 December 2014. Because this SMQ was not specific to the jaw localization, selection of cases based on anatomy was performed after data extraction. For each case, demographic and medical information was analysed, as well as data about notification (year of notification, year of occurrence, outcome, seriousness). Known associated factors for BRONJ were also documented: dentoalveolar surgery, glucocorticoids, chemotherapy, anti‐angiogenics, denosumab. Among 1404 SMQ notifications, 663 were located in the jaws and 629 were associated with bisphosphonate use. BRONJ reported in the database mainly affected women (n = 443, 71%) with an oncological indication (n = 440, 70%). BRONJ was considered as serious in 91%. Outcome was unfavourable for 92% of cases. Associated factors were identified for 70% of the patients. A peak of notification was noted in 2014 (13% of all cases), but on analysis by year of occurrence instead of by year of notification, this peak disappeared. SMQ ‘osteonecrosis’ appears to be an adequate tool to analyse BRONJ in a pharmacovigilance database. |
| |
| Keywords: | bisphosphonate osteonecrosis of the jaw pharmacovigilance spontaneous reporting |
|
|
